Cargando…
A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
BACKGROUND: This study sought to explore the biological significance of genetic variation in RAS wild-type metastatic colorectal cancer (mCRC) in the real world, the difference in the efficacy of cetuximab in the treatment of mCRC with different genetic variants and identify clinical features and ne...
Autores principales: | Tao, Huimin, Shen, Meng, Zhang, Xiaochang, Wang, Minghui, Wu, Yan, Sun, Hui, Ling, Chen, Yang, Ying, Chen, Kai, Li, Dapeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830345/ https://www.ncbi.nlm.nih.gov/pubmed/36636055 http://dx.doi.org/10.21037/jgo-22-1237 |
Ejemplares similares
-
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017) -
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021) -
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023) -
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017) -
[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)